Venaxis, a small medical diagnostics company in Castle Rock, CO, has raised $18.4 million through a public offering that closed Monday.
Venaxis (NASDAQ: APPY) is developing a protein biomarker-based blood test doctors can use to diagnose whether a patient has acute appendicitis. The test, known as APPY1, is intended to be used in emergency rooms to rule out whether a patient has developed the condition.
Help employers find you! Check out all the jobs and post your resume.
